THEMATIC POSTER SESSION

A Phase 3 open-label trial‍-‍in‍-‍progress evaluating garadacimab for prophylactic treatment of pediatric patients (aged 2‍–‍11 years) with hereditary angioedema

Presenting author: Prof. Andrea Zanichelli

ORAL PRESENTATION SESSION

Garadacimab improves quality of life in patients with hereditary angioedema: Results from the Phase 3 open‍-‍label extension study

Presenting author: Prof. Mar Guilarte

FLASH TALKS SESSION

Being attack-free is associated with improved quality of life for patients with hereditary angioedema treated with garadacimab: Post hoc analysis from the pivotal Phase 3 (VANGUARD) study

Presenting author: Dr. Emel Aygören‍-‍Pürsün

FLASH TALKS SESSION

Garadacimab provides early onset of protection against HAE attacks from Week 1 after first administration

Presenting author: Prof. Markus Magerl